Focus Partners Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Focus Partners Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$58.7M	Sell	131,435 -1,411	-1%	-$658K	0.07%	260
2025 Q4	$60.2M	Sell	132,846 -6,369	-5%	-$2.75M	0.07%	252
2025 Q3	$54.5M	Sell	139,215 -3,894	-3%	-$1.63M	0.09%	204
2025 Q2	$63.7M	Sell	143,109 -96	-0.1%	-$44.2K	0.14%	150
2025 Q1	$69.4M	Buy	143,205 +2,093	+1%	+$975K	0.17%	127
2024 Q4	$56.8M	Buy	141,112 +18,187	+15%	+$8.43M	0.15%	139
2024 Q3	$57.2M	Buy	122,925 +1,324	+1%	+$636K	0.18%	118
2024 Q2	$57M	Buy	121,601 +3,124	+3%	+$1.36M	0.19%	123
2024 Q1	$49.5M	Buy	118,477 +10,377	+10%	+$4.39M	0.4%	56
2023 Q4	$44M	Buy	+108,100	New	+$39.9M	0.58%	35

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Focus Partners Wealth's VRTX Position: Q1 2026 in Review

Focus Partners Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, selling an estimated $658K and leaving 131,435 shares worth $58.7M. The position accounts for 0.07% of the portfolio, ranked #260.

Focus Partners Wealth first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $69.4M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Focus Partners Wealth held 131,435 shares of Vertex Pharmaceuticals worth $58.7M as of Q1 2026.
Focus Partners Wealth sold 1,411 Vertex Pharmaceuticals shares in Q1 2026, an estimated $658K.
Vertex Pharmaceuticals made up 0.07% of Focus Partners Wealth's portfolio in Q1 2026, its #260 holding.
Focus Partners Wealth first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Focus Partners Wealth's Vertex Pharmaceuticals position peaked at $69.4M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.